Physician

Merla E Puray, M.D.

According to 2025 Medicare claims, Merla Puray, M.D. (NPI: 1952314205) practices hematology/oncology in the Merced, CA market, with the plurality of this provider's patient population coming from Merced, CA. Puray uses personal NPI as billing NPI and primary practice location at 95348-3133.

Puray's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 636 traditional Medicare patients, billed 159,662 HCPCS/CPT codes, and received $1,760,729 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 653 prescription claims across 112 beneficiaries totaling $3,468,559 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2020 DME data shows 88 claims. Open Payments data shows 55 records totaling $1,436. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,037,560 to $3,468,559. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	665	198,866	$1,948,953
2016	688	155,639	$2,002,969
2017	610	123,621	$1,695,276
2018	586	136,407	$1,760,000
2019	620	133,015	$1,835,631
2020	663	149,114	$1,939,939
2021	667	152,304	$1,830,953
2022	702	155,255	$1,629,206
2023	684	145,073	$1,747,410
2024	636	159,662	$1,760,729

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	181	1,153	$1,037,560
2016	176	1,206	$1,575,947
2017	149	883	$1,500,372
2018	151	927	$1,390,053
2019	145	816	$1,632,263
2020	156	1,021	$2,828,428
2021	140	799	$3,162,317
2022	145	696	$2,678,233
2023	109	597	$2,582,824
2024	112	653	$3,468,559

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	45	$38,431
2016	N/R	11	$1,114
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	88	$32,204
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	138	138	$170
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	114	249	$153
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	585	1,764	$105
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	315	702	$13
96372	Injection of drug or substance under skin or into muscle	134	405	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	91	3,000	$1,686,078
Revlimid	Lenalidomide	24	672	$414,648
Tagrisso	Osimertinib Mesylate	14	420	$238,305
Kisqali	Ribociclib Succinate	13	350	$206,816
Lenalidomide	Lenalidomide	14	392	$190,593

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	55	$1,436	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Merla E. Puray, M.D.?

Tedicare shows public-source Medicare data for Merla E. Puray, M.D. (NPI 1952314205), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Merla E. Puray, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Merla E. Puray, M.D.?

A separate primary affiliated billing organization is not shown for this profile in the available data.

Does Merla E. Puray, M.D. have Open Payments data?

Merla E. Puray, M.D. has 55 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.